#United States #San Francisco #Sling Therapeutics #Thyroid Eye Disease #Linsitinib

Sling Therapeutics to Present Clinical Trial Findings

Sling Therapeutics, Inc., a biopharmaceutical company in its later stages of development, is poised to unveil the topline results from its Phase 2b/3 LIDS clinical trial involving linsitinib. This significant presentation is scheduled for January 13, 2025, at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California. Dr. Raymond Douglas, the Chief Scientific Officer of Sling Therapeutics, will be the keynote speaker, outlining the company's initiatives and discussing the study's findings during a presentation at 5:00 PM PST.

Understanding Linsitinib's Role

Linsitinib is an innovative oral medication taken twice daily and is currently undergoing clinical trials to treat thyroid eye disease (TED). The drug specifically targets the IGF-1R pathway, which is the sole validated clinical target identified in TED, and this is significant considering that current FDA-approved treatments also focus on this pathway. By mitigating the impact of IGF-1R activation — a process responsible for inflammation and proptosis in TED — linsitinib hopes to offer a new treatment option with fewer side effects. This compound has demonstrated a robust safety profile after treating over 900 patients across multiple clinical trials for various conditions.

Cancer Threat Related to Thyroid Eye Disease

Thyroid Eye Disease (TED) is an autoimmune condition that poses a serious risk of progressive vision impairment, affecting approximately 70,000 individuals in the United States and a similar number in the EU. TED is most frequently associated with Graves' disease, which leads to disturbances in the IGF-1R signaling pathway resulting in excessive fibrous tissue formation behind the eyes. This leads to a range of distressing symptoms, including:

• - Pain and discomfort
• - Eye bulging (known as proptosis)
• - Double vision (diplopia)

Such symptoms can severely degrade the quality of life for those affected. Current treatments may involve either invasive surgical procedures or prolonged infusions that could cause adverse effects such as hearing loss, elevated blood sugar levels, or changes in menstrual cycles.

What This Presentation Means for the Future

As Sling Therapeutics approaches the mid-2025 target for launching a Phase 3 confirmatory trial, the results presented at the upcoming conference could significantly shift the landscape of treatment options for TED. By highlighting clinical findings from more than 900 patients and aligning on a potential pathway to simplified, convenient oral medication, Sling Therapeutics could improve care delivery while also easing the treatment burden on patients and healthcare providers alike.

In light of these developments, the therapeutic community will keenly observe Sling Therapeutics' findings and consider their implications for those suffering from this debilitating condition. For continued updates and more information on its initiatives, visit Sling Therapeutics' official website or follow their progress on social media platforms such as LinkedIn and X (formerly known as Twitter).